Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
(NASDAQ:CMPS) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovati...
How does COMP360’s safety and efficacy profile compare to competing psychedelic therapies (e.g., MDMA‑based programs) and existing PTSD treatments?
What is the expected timeline for Phase 3 trials, regulatory approval, and potential commercial launch of COMP360 for PTSD?
How will the Phase 2 results impact Compass Pathways’ short‑term stock price and market sentiment?
15 days ago